A pilot trial evaluating the sleep medication lemborexant in night-shift workers found no statistically significant overall difference in daytime sleep duration compared to placebo. The findings, originally reported by Prather and colleagues, became the focus of methodological analysis published in the Journal of Clinical Sleep Medicine by Eva Kartika Wulan Sari, Nining Maizura, and Putu Agus Indrawan. The correspondence evaluated whether the trial’s underlying data justify attributing the lack of an overall treatment effect to inadequate dosing.
In the primary trial, an exploratory analysis revealed that participants who received a 10-milligram dose of lemborexant reported greater daytime sleep duration in sleep diaries than participants who received a 5-milligram dose. However, sleep duration in the 10-milligram cohort did not differ significantly from that of the placebo group. According to Sari and colleagues, a key interpretive issue is whether this pattern validates the hypothesis that the trial produced a null primary result because the initial dosage was insufficient, an explanation the authors concluded is not established by the data.
The primary methodological concern centers on the nonrandomized nature of the dose comparison. Trial participants were initially randomized to receive either 5 milligrams of lemborexant or placebo. After one week, participants taking lemborexant consulted with researchers to decide whether to escalate their dose to 10 milligrams, a determination guided by each participant’s perceived benefit. Consequently, movement to the higher dose resulted from a post-randomization clinical decision rather than prospective, independent random assignment.
Because dose escalation was nonrandomized, participants who transitioned to the 10-milligram dose may have differed systematically from those who chose to remain on the 5-milligram regimen. In addition, the individual dose subgroups were very small, comprising only seven participants in one cohort and eight in the other. As a result, the observed divergence in diary-reported sleep duration could stem from a genuine pharmacological dose effect, participant self-selection linked to perceived benefit, or statistical chance, explanations the pilot trial cannot distinguish.
Sari and colleagues emphasized that an observed difference between nonrandomized dose subgroups does not demonstrate a causal dose-response relationship. Similarly, the authors noted that a nonsignificant statistical comparison against placebo does not prove an absolute absence of therapeutic benefit. Instead, the outcome demonstrates that the pilot investigation failed to establish an overall treatment effect, underscoring standard methodological guidance that requires transparent reporting and urges caution when interpreting subgroup outcomes without rigorous study designs.
To definitively test dosing effects in shift workers, the authors noted that a follow-up trial must prospectively randomize participants to clinically appropriate dose arms and placebo groups. Such an investigation would require prespecified primary between-group comparisons and complete reporting of effect estimates alongside confidence intervals. Until such rigorous evidence is collected, inadequate dosing must be treated as an unconfirmed hypothesis for future testing rather than an established conclusion from the existing trial data.
Subject of Research: Efficacy and dosing evaluation of lemborexant for daytime sleep in night-shift workers
Article Title: Context-dependent efficacy of lemborexant in shift workers: beyond average treatment effects
Article References: Sari, E. K. W., Maizura, N., & Indrawan, P. A. (2026). Context-dependent efficacy of lemborexant in shift workers: beyond average treatment effects. Journal of Clinical Sleep Medicine, 22(1), Article 222. https://doi.org/10.1007/s44470-026-00236-y
Image Credits: AI Generated
DOI: 10.1007/s44470-026-00236-y
Keywords: lemborexant, daytime sleep duration, night-shift workers, placebo-controlled trial, pilot trial, dose escalation, treatment efficacy, subgroup analysis, randomized comparison, sleep diary, dose-response relationship, perceived benefit, inadequate dosing hypothesis, Journal of Clinical Sleep Medicine, trial methodology, selection bias, statistical significance
News Source: Ophelia Keating. (November 15, 2026). Lemborexant Shows No Significant Daytime Sleep Improvement in Night Shift Workers. Scienmag.



